Comerica Bank Sells 7,518 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Comerica Bank lessened its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 26.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,540 shares of the company's stock after selling 7,518 shares during the period. Comerica Bank's holdings in Apogee Therapeutics were worth $930,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its position in Apogee Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company's stock valued at $432,000 after acquiring an additional 892 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 17.3% in the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company's stock worth $295,000 after purchasing an additional 960 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Apogee Therapeutics by 8.9% during the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company's stock valued at $552,000 after purchasing an additional 1,000 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Apogee Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company's stock valued at $1,736,000 after buying an additional 1,212 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Apogee Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 52,720 shares of the company's stock worth $2,388,000 after buying an additional 1,750 shares in the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

APGE has been the topic of a number of research analyst reports. Wedbush restated an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Citigroup initiated coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has an average rating of "Buy" and a consensus target price of $94.60.

Apogee Therapeutics Stock Down 0.0%

APGE traded down $0.02 during trading on Friday, hitting $40.62. The company's stock had a trading volume of 444,797 shares, compared to its average volume of 522,736. The business's 50 day simple moving average is $36.65 and its 200-day simple moving average is $41.30. The firm has a market cap of $1.82 billion, a PE ratio of -16.79 and a beta of 1.70. Apogee Therapeutics, Inc. has a one year low of $26.20 and a one year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. Equities research analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 1,590 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This trade represents a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the transaction, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. The trade was a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,175 shares of company stock valued at $587,191 over the last quarter. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.